相关实验视频

Updated: Jun 24, 2025

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

在转移性癌症中,DUX4是免疫逃避和免疫治疗失败的常见驱动因素

Jose Mario Bello Pineda^1,2,3,4, Robert K Bradley^1,2,3

¹Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, United States.

|June 3, 2024

概括

胚胎转录因子DUX4在转移性癌症中常见,阻碍免疫反应并降低免疫治疗的有效性. 向DUX4可以改善对现有疗法耐药的晚期癌症患者的治疗方法.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

癌症免疫逃避是转移性癌症免疫疗法失败的关键原因.
胚胎转录因子DUX4抑制干扰素γ信号传递和抗原呈现.
在一些原发性瘤中观察到异常的DUX4表达.

研究的目的:

调查转移性癌症中DUX4表达的流行率.
确定DUX4表达与免疫细胞排斥和免疫治疗反应的关联.
评估DUX4作为患者生存的预后生物标志物.

主要方法:

在各种转移性癌症类型中分析DUX4表达.
DUX4表达与瘤中免疫细胞透的相关性.
在尿路癌患者中对PD-L1阻塞的反应的评估.
考虑瘤突变负担和临床因素的生存分析.

主要成果:

DUX4表达在~10-50%的晚期膀,乳腺,脏,前列腺和皮肤癌中普遍存在.
DUX4表达与免疫细胞排除和减少对PD-L1阻塞的反应相关.
DUX4是生存的重要预测因素,与中位数生存时间减少超过一年有关.

结论:

DUX4表达是转移性瘤的常见特征,与免疫疗法耐药性有关.
DUX4可以作为检查点免疫治疗反应的预测生物标志物.
在癌症中,DUX4是克服免疫疗法耐药性的潜在治疗标.

关键词:

DUX4X4 的使用情况抗原呈现的呈现方式.癌症生物学癌症生物学遗传学遗传学遗传学是一个基因组学就是基因组学.人类人类人类人类人类人类人类免疫检查点抑制抑制免疫检查点抑制转移性癌症是转移性的癌症.

更多相关视频

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...